Survodutide common uses, half-life, side effects and more

Survodutide is an investigational once-weekly injectable peptide developed for obesity and metabolic liver disease. It pairs the appetite-lowering action of GLP-1 drugs with an added glucagon action that raises energy use and reduces liver fat. Human trials report both weight loss and reductions in liver fat. It is not approved by any health authority in any country. People who obtain it outside a clinical trial use unapproved research-grade material of unverified identity, strength, and sterility.

• Weight loss in obesity
• Reducing liver fat in metabolic liver disease
• Improving MASH with liver fibrosis
• Blood sugar control in type 2 diabetes
• Community use as an add-on to tirzepatide or retatrutide

Once weekly

Once-weekly subcutaneous injection. Community users start low at a few hundred micrograms up to about 0.6 mg weekly and escalate slowly over several weeks because the glucagon action makes nausea worse than a pure GLP-1 drug. Most settle between about 1.8 mg and 3.6 mg weekly. Many hold near 1.8 to 2 mg. Some run about 1 mg as an add-on to tirzepatide or retatrutide rather than on its own. Clinical trials titrate higher and step up every four weeks toward a 3.6 mg or 6 mg maintenance dose. The higher numbers that some vendor pages sell as a fixed protocol trace to those trials rather than to first-hand use.

Survodutide has a long half-life of roughly 6 to 7 days. This is long enough to support once-weekly subcutaneous dosing. Reported values vary and no exact human figure appears in open sources.

• Nausea, vomiting, diarrhea, and constipation that are worst while the dose is increasing
• Reduced appetite and feeling full early
• Fatigue, indigestion, and headache
• Resting heart rate rise of a few beats per minute from the glucagon action
• Gallstones that become more likely with rapid weight loss
• Dehydration and kidney strain if vomiting is severe

Survodutide is a single peptide that switches on both the GLP-1 receptor and the glucagon receptor. The GLP-1 arm curbs appetite, raises glucose-driven insulin release, and slows stomach emptying. The glucagon arm does two things a GLP-1-only drug cannot. It raises energy expenditure and makes the liver burn more of its stored fat. The two arms are close to balanced in the test tube. Albumin binding in the blood then tilts activity several fold toward GLP-1. That same glucagon action also drives stronger nausea and a small rise in heart rate. A C18 fatty diacid chain binds albumin and keeps the peptide circulating for weekly dosing. Both receptor arms are confirmed active in people.

Survodutide has been tested in registered phase 2 and phase 3 human trials. A phase 2 obesity trial showed about 15% mean weight loss at the top dose over 46 weeks. A phase 2 liver trial improved MASH in many patients without worsening fibrosis. The phase 3 SYNCHRONIZE-1 obesity trial reported roughly 13% mean weight loss at 76 weeks. People who stayed on treatment lost closer to 17%. The phase 3 SYNCHRONIZE-MASLD trial cut liver fat by at least 30% in up to 84% of the top-dose group versus about a quarter on placebo. The evidence is recent and still short in duration. The cardiovascular outcomes trial and the biopsy-based liver trials have not finished. It is not approved anywhere and has no pregnancy or lactation data.

• Gray-market survodutide is unapproved and can vary in identity, strength, purity, and sterility
• Gastrointestinal side effects are heavier than with the approved GLP-1 drugs and made about one in five people in trials stop treatment
• The GLP-1 class carries a rodent-based thyroid tumor signal that makes use inadvisable with a personal or family history of medullary thyroid cancer or MEN2
• Acute pancreatitis is a class risk that makes severe or lasting abdominal pain a reason for prompt medical evaluation
• The glucagon action raises resting heart rate and can matter for anyone with existing heart disease
• Survodutide has no reproductive safety data and should be avoided in pregnancy, breastfeeding, or when trying to conceive